Genomes and Genes
Summary: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.
Publications234 found, 100 shown here
- Levonorgestrel-releasing intrauterine system: uses and controversiesLuis Bahamondes
Department of Obstetrics and Gynecology, School of Medicine, University of Campinas, Caixa Postal 6181, Campinas, SP, Brazil
Expert Rev Med Devices 5:437-45. 2008This article provides a perspective on the use of the levonorgestrel-releasing intrauterine system as a contraceptive method and as therapy in different situations, as well as presenting the corresponding controversies and unresolved ..
- Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrelHans Joachim Ahrendt
Gynekologická a Porodnická Ambulance, Prague, Czech Republic
Contraception 80:436-44. 2009..E2V/DNG; administered using a dynamic dosing regimen) with a monophasic OC containing ethinyl estradiol 20 mcg/levonorgestrel 100 mcg (EE/LNG). E2V releases estradiol (E2), which is identical to endogenously produced 17beta-estradiol.
- Use of the levonorgestrel releasing-intrauterine system in nulliparous women--a non-interventional study in SwedenLena Marions
Department of Obstetrics and Gynaecology, Division of Women s and Children s Health, Karolinska University Hospital Institutet, Stockholm, Sweden
Eur J Contracept Reprod Health Care 16:126-34. 2011To evaluate the insertion procedure and continuation rates of the levonorgestrel releasing-intrauterine system (LNG-IUS) in nulliparous women who, due to fear of complications, are often denied this very effective contraceptive method.
- Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9Øjvind Lidegaard
Gynaecological Clinic 4232, Rigshospitalet, University of Copenhagen, Denmark
BMJ 343:d6423. 2011..To assess the risk of venous thromboembolism from use of combined oral contraceptives according to progestogen type and oestrogen dose...
- Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine systemAnne Orbo
Institute of Medical Biology, University of Tromsø, Norway
Acta Obstet Gynecol Scand 89:1438-46. 2010To investigate whether regression of endometrial hyperplasia observed after 3 months of treatment with levonorgestrel impregnated intrauterine system device (LNG-IUS) was sustained after 6 months and whether these effects were still ..
- Proteomic analysis of testis biopsies in men treated with injectable testosterone undecanoate alone or in combination with oral levonorgestrel as potential male contraceptiveYugui Cui
Laboratory of Reproductive Medicine, Department of Histology and Embryology, and Center of Clinical Reproductive Medicine, The First Affiliated Hospital, Nanjing Medical University, Nanjing 210029, China
J Proteome Res 7:3984-93. 2008Treatment with injectable testosterone undecanoate (TU) alone or in combination with oral levonorgestrel (LNG) resulted in marked decreases in sperm concentrations...
- Levonorgestrel-releasing intrauterine system or medroxyprogesterone for heavy menstrual bleeding: a randomized controlled trialAndrew M Kaunitz
Department of Obstetrics and Gynecology, University of Florida College of Medicine Jacksonville, Jacksonville, Florida, USA
Obstet Gynecol 116:625-32. 2010To compare the efficacy and safety of the levonorgestrel-releasing intrauterine system and oral medroxyprogesterone acetate in the treatment of idiopathic heavy menstrual bleeding.
- Ease of insertion and clinical performance of the levonorgestrel-releasing intrauterine system in nulligravidasM Valeria Bahamondes
Department of Obstetrics and Gynecology, University of Campinas, Campinas, Brazil
Contraception 84:e11-6. 2011Despite the high contraceptive efficacy and the additional noncontraceptive benefits of the levonorgestrel-releasing intrauterine system (LNG-IUS), concerns persist with respect to its use in nulligravidas...
- Efficacy, acceptability and side effects of the levonorgestrel intrauterine system for menorrhagiaA Kriplani
Department of Obstetrics and Gynecology, All India Institute of Medical Sciences, New Delhi, India
Int J Gynaecol Obstet 97:190-4. 2007To evaluate the efficacy, acceptability, and possible side effects of a levonorgestrel-releasing intrauterine system for menorrhagia.
- transient scrotal hyperthermia and levonorgestrel enhance testosterone-induced spermatogenesis suppression in men through increased germ cell apoptosisChristina Wang
Department of Medicine, Harbor University of California, Los Angeles, Torrance, California 90509, USA
J Clin Endocrinol Metab 92:3292-304. 2007..In rodents and monkeys, a combination of hormonal and physical agents accelerates germ cell death...
- A pharmacokinetic study with a low-dose oral contraceptive containing 20 microg ethinylestradiol plus 100 microg levonorgestrelJ Endrikat
Schering AG, Berlin, Germany
Eur J Contracept Reprod Health Care 7:79-90. 2002..pharmacokinetics of a dose-reduced oral contraceptive containing 20 microg ethinylestradiol (EE) + 100 microg levonorgestrel (LNG) in 18 young, healthy females...
- The levonorgestrel-releasing intrauterine system in human immunodeficiency virus-infected women: a 5-year follow-up studyOskari Heikinheimo
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
Am J Obstet Gynecol 204:126.e1-4. 2011We sought to assess the effects of long-term use and safety of the levonorgestrel-releasing (LNG)-intrauterine system (IUS) among human immunodeficiency virus (HIV)-infected women in comparison with HIV-infected women not using the device.
- Pharmacokinetic study of different dosing regimens of levonorgestrel for emergency contraception in healthy womenElof Johansson
Center for Biomedical Research, The Population Council, New York, NY, USA
Hum Reprod 17:1472-6. 2002b>Levonorgestrel (LNG) is a commonly used progestin for emergency contraception; however, little is known about its pharmacokinetics and optimal dose for use.
- Hysterectomy, endometrial destruction, and levonorgestrel releasing intrauterine system (Mirena) for heavy menstrual bleeding: systematic review and meta-analysis of data from individual patientsL J Middleton
Birmingham Clinical Trials Unit, University of Birmingham, Birmingham B15 2TT
BMJ 341:c3929. 2010..endometrial destruction (both "first generation" hysteroscopic and "second generation" non-hysteroscopic techniques), and the levonorgestrel releasing intrauterine system (Mirena) in the treatment of heavy menstrual bleeding.
- The evaluation of the effectiveness of an intrauterine-administered progestogen (levonorgestrel) in the symptomatic treatment of endometriosis and in the staging of the diseaseF B Lockhat
Department of Obstetrics and Gynaecology, Robert Kilpatrick Clinical Sciences Building, Leicester Royal Infirmary, Leicester LE2 7LX, UK
Hum Reprod 19:179-84. 2004..A progestogen (levonorgestrel) administered via an intrauterine system (Lng-IUS) has been demonstrated to improve symptoms of endometriosis; ..
- A randomized trial to compare 24 h versus 12 h double dose regimen of levonorgestrel for emergency contraceptionSuk Wai Ngai
Department of Obstetrics and Gynecology, University of Hong Kong, Queen Mary Hospital, 102 Pokfulam Road, Hong Kong SAR, China
Hum Reprod 20:307-11. 2005b>Levonorgestrel (0.75 mg given for two doses 12 h apart) has been proven to be an effective regimen for emergency contraception when the first dose is given within 72 h of unprotected coitus...
- Ulipristal acetate versus levonorgestrel for emergency contraception: a randomised non-inferiority trial and meta-analysisAnna F Glasier
National Health Service Lothian, Edinburgh, UK
Lancet 375:555-62. 2010..We compared the efficacy and safety of ulipristal acetate with levonorgestrel for emergency contraception.
- Risk of nonfatal venous thromboembolism with oral contraceptives containing norgestimate or desogestrel compared with oral contraceptives containing levonorgestrelSusan S Jick
Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
Contraception 73:566-70. 2006..have about twice the risk for venous thromboembolism (VTE) compared to users of older OCs containing levonorgestrel. Estimates of the risk for VTE among users of norgestimate-containing OCs compared to other OCs, however, are ..
- Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysisH Jick
Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
BMJ 321:1190-5. 2000To compare the risk of idiopathic venous thromboembolism among women taking third generation oral contraceptives (with gestodene or desogestrel) with that among women taking oral contraceptives with levonorgestrel.
- Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims dataSusan S Jick
Boston Collaborative Drug Surveillance Program, Boston University School of Medicine, Lexington, MA 02421, USA
BMJ 342:d2151. 2011To compare the risk of non-fatal venous thromboembolism in women receiving oral contraceptives containing drospirenone with that in women receiving oral contraceptives containing levonorgestrel.
- Expressions of steroid receptors and Ki67 in first-trimester decidua and chorionic villi exposed to levonorgestrel used for emergency contraceptionChun Xia Meng
Department of Woman and Child Health, Division of Obstetrics and Gynecology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Fertil Steril 91:1420-3. 2009b>Levonorgestrel (1.5 mg) is commonly used for emergency contraception to prevent an unwanted pregnancy after an unprotected intercourse. We found that postovulatory administration of 1...
- A randomized, controlled trial of a low-dose contraceptive containing 20 microg of ethinyl estradiol and 100 microg of levonorgestrel for acne treatmentD Thiboutot
Division of Dermatology, Pennsylvania State University, Hershey, USA
Fertil Steril 76:461-8. 2001OBJECTIVE: To evaluate the efficacy of a low-dose oral contraceptive (OC) containing 100 microg of levonorgestrel (LNG) and 20 microg of ethinyl estradiol (EE) compared with placebo for the treatment of moderate acne...
- Intrauterine devices and adolescentsMelanie A Gold
Division of Adolescent Medicine, Department of Pediatrics, University of Pittsburgh School of Medicine, PA 15213, USA
Curr Opin Obstet Gynecol 20:464-9. 2008..The purpose of this review is to inform the reader of new information published on intrauterine devices (IUDs) and adolescents...
- Use of a levonorgestrel-releasing intrauterine device in the treatment of rectovaginal endometriosisL Fedele
Department of Maternal and Child Health, Biology and Genetics, University of Verona, Verona, Italy
Fertil Steril 75:485-8. 2001To evaluate the effectiveness of a levonorgestrel-releasing IUD as therapy for endometriosis of the rectovaginal septum.
- Pharmacokinetics of levonorgestrel 0.75 mg tabletsKarin Kook
Salamandra LLC, Chevy Chase, MD, USA
Contraception 66:73-6. 2002This study examined plasma levonorgestrel (LNG) concentrations and pharmacokinetics following oral administration of a single LNG 0.75 mg tablet. Sixteen healthy female volunteers 19-44 years old enrolled in the study...
- Assessment of menstrual blood loss in Belgian users of the frameless copper-releasing IUD with copper surface area of 200 mm2 and users of a copper-levonorgestrel-releasing intrauterine systemD Wildemeersch
Contrel Research, Ghent, Belgium
Contraception 70:169-72. 2004This study was conducted to evaluate the effect of a miniaturized frameless copper IUD (GyneFix 200 small) and a copper-levonorgestrel (GynePlant) intrauterine system (IUS) on the amount of menstrual blood loss (MBL).
- Postoperative medical treatment of chronic pelvic pain related to severe endometriosis: levonorgestrel-releasing intrauterine system versus gonadotropin-releasing hormone analogueYesim Bayoglu Tekin
Department of Obstetric and Gynecology, Agri Patnos Public Hospital, Ministry of Health, Patnos Agri, Turkey
Fertil Steril 95:492-6. 2011To compare efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena) with depot GnRH analogue (GnRH-a; gosareline acetate; Zoladex) on endometriosis-related chronic pelvic pain (CPP) in patients with severe ..
- Translational research with progesterone receptor modulator motivated by the use of levonorgestrel-releasing intrauterine systemTakeshi Maruo
Kobe Children s Hospital and Feto Mternal Medical Center, Kobe 654 0081, Japan
Contraception 82:435-41. 2010The use of levonorgestrel-releasing intrauterine system (LNG-IUS) is effective for management of menorrhagic women with uterine myomas because of reduction in menorrhagia...
- Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysisIoannis D Gallos
Academic Unit of Obstetrics and Gynaecology, Birmingham Women s Hospital, Birmingham, UK
Am J Obstet Gynecol 203:547.e1-10. 2010To conduct a systematic review and metaanalysis of studies evaluating the regression rate of endometrial hyperplasia with oral progestogens and levonorgestrel-releasing intrauterine system.
- The effects of levonorgestrel on various sperm functionsWilliam S B Yeung
Department of Obstetrics and Gynaecology, The University of Hong Kong, Hong Kong, China
Contraception 66:453-7. 2002Two doses of 750-microg levonorgestrel at 12 h apart is one of the regimens for emergency contraception. The mechanism of action of this regimen is not fully known...
- Levonorgestrel-releasing intrauterine system vs. endometrial thermal ablation for menorrhagiaTheodoros D Theodoridis
1st Department of Obstetrics and Gynaecology, Papageorgiou General Hospital, Aristotle University of Thessaloniki, Periferiaki Odos Thessalonikis, N Efkarpia, Thessaloniki, Greece
Hormones (Athens) 8:60-4. 2009To evaluate the efficacy of a Levonorgestrel-releasing Intrauterine System (LNG-IUS) in controlling menorrhagia in comparison with endometrial thermal rollerball ablation.
- Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese menYou lun Gui
Shanghai Institute of Planned Parenthood Research, 2140 Xie Tu Rd, Shanghai 200032, China
J Androl 25:720-7. 2004..degrees of sperm suppression in white men, we hypothesized that the combination of TU and the progestin levonorgestrel (LNG) would result in improved spermatogenic suppression in Chinese men...
- Use of three-dimensional ultrasound in evaluating the intrauterine position of a levonorgestrel-releasing intrauterine systemEfraim Zohav
Department of Obstetrics and Gynecology, Barzilai Medical Center, Ashkelon, 78278, Israel
Reprod Biomed Online 14:495-7. 2007..reports the first case of three-dimensional (3-D) transvaginal ultrasonography (TVS) imaging of malpositioned levonorgestrel-releasing intrauterine system (LNG-IUS)...
- The in vitro effect of levonorgestrel on the acrosome reaction of human spermatozoa from fertile menL Bahamondes
Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas UNICAMP, Caixa Postal 6181, 13084 971, Campinas, Sao Paulo, Brazil
Contraception 68:55-9. 2003The objective of the study was to evaluate the effect of levonorgestrel (LNG) on the occurrence of acrosome reaction (AR) of capacitated spermatozoa from fertile men. A total of 20 semen samples from four fertile men were evaluated...
- A randomized trial of mifepristone (10 mg) and levonorgestrel for emergency contraceptionH Hamoda
Department of Obstetrics and Gynaecology, University of Aberdeen, United Kingdom
Obstet Gynecol 104:1307-13. 2004To compare the efficacy, patient acceptability and adverse effects of low-dose mifepristone (10 mg) with the levonorgestrel regimen (2 doses of 750 microg given 12 hours apart) for emergency contraception.
- Long-term treatment of menorrhagia with levonorgestrel intrauterine system versus endometrial resectionIlkka Rauramo
The Finnish Medical Society Duodecim, Helsinki, Finland
Obstet Gynecol 104:1314-21. 2004The purpose of this study was to compare the long-term efficacy of the levonorgestrel intrauterine system and transcervical resection of the endometrium in the treatment of menorrhagia.
- Treatment of endometrial hyperplasia without atypia in peri- and postmenopausal women with a levonorgestrel intrauterine deviceSergio Haimovich
Department of Obstetrics and Gynecology, Hospital Universitari del Mar, Autonomous University of Barcelona, Barcelona, Spain
Menopause 15:1002-4. 2008To assess the effectiveness of the Mirena levonorgestrel-releasing intrauterine system (LNG-IUS) in peri- and postmenopausal women with endometrial hyperplasia without atypia.
- Practice tips. Inserting the levonorgestrel intrauterine system: off-label useCatherine Caron
Department of Family Medicine, University of Ottawa, Ontario
Can Fam Physician 53:643-4. 2007
- The effect of levonorgestrel-releasing intrauterine system use on menstrual blood loss and the hemostatic, fibrinolytic/inhibitor systems in women with menorrhagiaS C L Koh
Department of Obstetrics and Gynaecology, National University of Singapore, Yong Loo Lin School of Medicine, National University Hospital, Singapore, Singapore
J Thromb Haemost 5:133-8. 2007..The levonorgestrel-releasing intrauterine system (LNG-IUS) ranks higher than medical treatments in terms of efficacy, comparable ..
- Therapeutic levels of levonorgestrel detected in blood plasma of fish: results from screening rainbow trout exposed to treated sewage effluentsJerker Fick
Department of Chemistry, Umea University, Umea, Sweden
Environ Sci Technol 44:2661-6. 2010..The progestin pharmaceutical levonorgestrel was detected in fish blood plasma at concentrations (8...
- The in vitro effect of emergency contraception doses of levonorgestrel on the acrosome reaction of human spermatozoaKaren Saboya Brito
Human Reproduction Unit, Department of Obstetrics and Gynecology, School of Medicine, Universidade Estadual de Campinas UNICAMP, 13084 971 Campinas, Brazil
Contraception 72:225-8. 2005The aim of this study was to evaluate the effect of three concentrations of levonorgestrel (LNG) comparable to the levels found in serum following ingestion of LNG as emergency contraception (EC) on the acrosome reaction (AR) of ..
- A randomized controlled trial of hysterectomy or levonorgestrel-releasing intrauterine system in the treatment of menorrhagia-effect on FSH levels and menopausal symptomsK Halmesmäki
Department of Obstetrics and Gynecology, Central Hospital of Päijät Häme, Keskussairaalankatu 7, 15850 Lahti, Finland
Hum Reprod 19:378-82. 2004The purpose of this study was to compare the effects of hysterectomy and a levonorgestrel-releasing intrauterine system (LNG-IUS) on serum FSH levels and menopausal symptoms.
- Cost-effectiveness and quality of life associated with heavy menstrual bleeding among women using the levonorgestrel-releasing intrauterine systemPaul D Blumenthal
Department of Obstetrics and Gynecology, Stanford University, Stanford, USA
Int J Gynaecol Obstet 112:171-8. 2011To review the literature for economic and health-related quality of life outcomes data associated with the use of the levonorgestrel-releasing intrauterine system (LNG-IUS) in the management of heavy menstrual bleeding.
- Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006)Taek Sang Lee
Department of Obstetrics and Gynecology, Gangnam CHA Medical Center, CHA University, 650 9, Yoksam Dong, Gangnam Gu, Seoul 135 913, Republic of Korea
Jpn J Clin Oncol 41:817-9. 2011A prospective multicenter trial has been commenced in Korea to investigate the treatment efficacy of the levonorgestrel-releasing intrauterine system in patients with endometrial hyperplasia...
- Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research DatabaseLianne Parkin
Department of Preventive and Social Medicine, Dunedin School of Medicine, University of Otago, New Zealand
BMJ 342:d2139. 2011To examine the risk of non-fatal idiopathic venous thromboembolism in current users of a combined oral contraceptive containing drospirenone, relative to current users of preparations containing levonorgestrel.
- Risk of venous thromboembolism from oral contraceptives containing gestodene and desogestrel versus levonorgestrel: a meta-analysis and formal sensitivity analysisS Hennessy
Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
Contraception 64:125-33. 2001..and gestodene are associated with an increased risk of venous thromboembolism (VTE) versus OCs containing levonorgestrel. We were interested in synthesizing the available data, exploring explanations for mixed results, and ..
- The levonorgestrel-releasing intrauterine system in heavy menstrual bleeding: a benefit-risk reviewAndrew M Kaunitz
Department of Obstetrics and Gynecology, University of Florida College of Medicine Jacksonville, FL 32209, USA
Drugs 72:193-215. 2012..databases to evaluate the clinical evidence and provide an update on the risks and benefits of using the levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of HMB...
- The cost-effectiveness of the levonorgestrel-releasing intrauterine system for the treatment of idiopathic heavy menstrual bleeding in the United StatesMichael L Ganz
United BioSource Corporation, Lexington, MA 02420, USA
Value Health 16:325-33. 2013..Our objective was to evaluate the cost-effectiveness of the levonorgestrel-releasing intrauterine system (LNG-IUS) compared with other therapies for idiopathic heavy menstrual bleeding.
- Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilizationO Meirik
United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)/World Health Organization (WHO)/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Geneva, Switzerland
Obstet Gynecol 97:539-47. 2001OBJECTIVE: To evaluate safety and efficacy of levonorgestrel-releasing contraceptive implants (Norplant; Leiras Oy, Turku, Finland) in developing countries. METHODS: We used controlled cohort methodology...
- Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrelChristine Klipping
Dinox BV, Groningen, The Netherlands
Drugs R D 11:159-70. 2011..Based on previous studies, it is expected that this estradiol-based COC will have a reduced hepatic effect compared with COCs containing ethinylestradiol with regard to proteins controlling the hemostatic balance...
- Levonorgestrel intra-uterine system as a treatment option for complex endometrial hyperplasiaZeina J Haoula
Department of Obstetrics and Gynaecology, University Hospital, Queens Medical Centre, Nottingham, NG7 2UH, United Kingdom
Eur J Obstet Gynecol Reprod Biol 159:176-9. 2011The objective of this study was to evaluate the potential treatment of atypical and non-atypical endometrial hyperplasia with the levonorgestrel intrauterine system (LNG-IUS).
- Clinical outcome of levonorgestrel intra-uterine system in idiopathic menorrhagiaB Chattopdhyay
Department of Obstetrics and Gynaecology, Lady Hardinge Medical College, New Delhi, India
Eur Rev Med Pharmacol Sci 15:764-8. 2011To evaluate the efficacy, acceptability and side effects of levonorgestrel intrauterine system in patients with idiopathic menorrhagia.
- A biodegradable levonorgestrel-releasing implant made of PCL/F68 compound as tested in rats and dogsGuilei Ma
The Tianjin Key Laboratory of Biomaterials, Institute of Biomedical Engineering, Peking Union Medical College and Chinese Academy of Medical Sciences, Nankai District, Tianjin 300192, China
Contraception 74:141-7. 2006..Our objective was to report preclinical studies on a biodegradable long-acting contraceptive implant...
- Ibuprofen prophylaxis for levonorgestrel-releasing intrauterine system insertion: a randomized controlled trialJulie Chor
Department of Obstetrics and Gynecology, John H Stroger Jr Hospital of Cook County, Chicago, IL 60612, USA
Contraception 85:558-62. 2012Despite the high efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) in preventing pregnancy, uptake of the intrauterine devices remains low in the United States...
- Circulating sex hormones and endometrial stromelysin-1 (matrix metalloproteinase-3) at the start of bleeding episodes in levonorgestrel-implant usersE Marbaix
Christian de Duve Institute of Cellular Pathology, Department of Pathology, Medical School of the Université catholique de Louvain, Bruxelles, Belgium
Hum Reprod 15:120-34. 2000Unpredictable endometrial bleeding is the major side-effect of levonorgestrel-releasing s.c. implants (Norplant), otherwise a method of choice for long-term contraception...
- The levonorgestrel-releasing intrauterine system provides a reliable, long-term treatment option for women with idiopathic menorrhagiaJan Endrikat
Bayer HealthCare, Berlin, Germany
Arch Gynecol Obstet 285:117-21. 2012Idiopathic menorrhagia (IM) is an important clinical challenge. The levonorgestrel-releasing intrauterine system (LNG IUS) provides an effective treatment option as shown by multiple small clinical studies...
- Different effects of oral contraceptives containing levonorgestrel or desogestrel on plasma lipoproteins and coagulation factor VIIMarianne van Rooijen
Department of Woman and Child Health, Division of Obstetrics and Gynaecology, King Gustaf V Research Institute, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
Am J Obstet Gynecol 186:44-8. 2002..The objective of the study was to compare the effects of two different combined oral contraceptives on levels of plasma lipoproteins and coagulation factor VII...
- The benefits and risks of using a levonorgestrel-releasing intrauterine system for contraceptionDiana Mansour
New Croft Centre, NE1 6ND Newcastle upon Tyne, UK
Contraception 85:224-34. 2012The contraceptive profile of the levonorgestrel-releasing intrauterine system (LNG-IUS; Mirena®) is well established, with efficacy similar to that achieved with sterilization and rapid return to fertility after discontinuation of use...
- Proultraflexible lipid vesicles for effective transdermal delivery of levonorgestrel: development, characterization, and performance evaluationSubheet Jain
Department of Pharmaceutical Sciences and Drug Research, Punjabi University, Patiala, Punjab, India
AAPS PharmSciTech 6:E513-22. 2005..of new vesicular drug carrier system protransfersomes for transdermal delivery of the contraceptive agent, levonorgestrel. Protransfersome gel (PTG) formulations of levonorgestrel were prepared and characterized for vesicle shape, ..
- The levonorgestrel intrauterine system is an effective treatment in selected obese women with abnormal uterine bleedingGeorge A Vilos
St Joseph s Health Care, Department of Obstetrics and Gynecology, The University of Western Ontario, London, Ontaio, Canada
J Minim Invasive Gynecol 18:75-80. 2011To evaluate the use of the levonorgestrel intrauterine system (LNG-IUS) in obese premenopausal women with abnormal uterine bleeding (AUB).
- [Effects of levonorgestrel-releasing intrauterine system on pain and recurrence associated with endometriosis and adenomyosis]Shan Deng
Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing 100730, China
Zhonghua Fu Chan Ke Za Zhi 41:664-8. 2006To observe the effects of levonorgestrel-releasing intrauterine system (LNG-IUS) in treatment of pain associated with endometriosis (EM) and adenomyosis (AM), and in prevention of disease recurrence.
- Levonorgestrel intrauterine system versus medical therapy for menorrhagiaJanesh Gupta
School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom
N Engl J Med 368:128-37. 2013..In a pragmatic, multicenter, randomized trial, we compared the levonorgestrel-releasing intrauterine system (levonorgestrel-IUS) with usual medical treatment in women with menorrhagia who ..
- Effect of mifepristone and levonorgestrel on expression of steroid receptors in the human Fallopian tubeA Christow
Division of Obstetrics and Gynecology, Department of Woman and Child Health, Karolinska Hospital, S 171 76 Stockholm, Sweden
Mol Hum Reprod 8:333-40. 2002It is likely that mifepristone or levonorgestrel in the future will find extended use for contraceptive purposes. It is therefore essential to characterize the modes of action of these compounds...
- The synthetic progestogen, Levonorgestrel, but not natural progesterone, affects male mate calling behavior of Xenopus laevisFrauke Hoffmann
Department of Ecophysiology and Aquaculture, Leibniz Institute of Freshwater Ecology and Inland Fisheries, Berlin, Germany
Gen Comp Endocrinol 176:385-90. 2012..to three environmentally relevant concentrations (10(-7) M, 10(-8) M and 10(-10) M) of the synthetic progestin Levonorgestrel (LNG) and the corresponding natural steroid progesterone (PRG), respectively...
- The risk of deep venous thrombosis associated with injectable depot-medroxyprogesterone acetate contraceptives or a levonorgestrel intrauterine deviceAstrid van Hylckama Vlieg
Department of Clinical Epidemiology, Leiden University Medical Center, C7 P, PO Box 9600, NL 2300 RC Leiden, The Netherlands
Arterioscler Thromb Vasc Biol 30:2297-300. 2010..of venous thrombosis associated with nonoral contraceptives (ie, injectable depot-medroxyprogesterone acetate contraceptives, hormone [levonorgestrel]-releasing intrauterine devices, a contraceptive patch, or a contraceptive implant).
- Postoperative levonorgestrel-releasing intrauterine system for pelvic endometriosis-related pain: a randomized controlled trialPrasong Tanmahasamut
Gynecologic Endocrinology Unit, Division of Reproductive Medicine, Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
Obstet Gynecol 119:519-26. 2012To estimate the effectiveness of a postoperative levonorgestrel-releasing intrauterine system for relieving pelvic pain in patients with endometriosis.
- Efficacy of levonorgestrel intrauterine system (LNG-IUS) for abnormal uterine bleeding and contraceptionNabia Tariq
Department of Obstetrics and Gynaecology, Shifa College of Medicine, Islamabad
J Coll Physicians Surg Pak 21:210-3. 2011To find out clinical response, side effects and patients' acceptability of levonorgestrel-releasing intrauterine system (LNG-IUS).
- The pharmacokinetics of 750 microg levonorgestrel following administration of one single dose or two doses at 12- or 24-h intervalD Tremblay
Laboratoire HRA Pharma, 19, , 75020 Paris, France
Contraception 64:327-31. 2001The administration of two tablets of 750 microg levonorgestrel at a 12- to 24-h interval has been shown to be a safe and effective means of emergency contraception, and Norlevo/Vikela (N/V) is a dedicated product for this indication...
- The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot studyAlexandr I Pashov
Department of Obstetrics and Gynecology, State Medical University n a V F Voyno Yasenetsky, Krasnoyarsk, Russia
Gynecol Endocrinol 28:559-61. 2012..After the third injection of 3.75 mg of leuproreline acetate, the levonorgestrel intrauterine hormonal system containing 52 mg levonorgestrel (Mirena®, Bayer, Germany) was inserted for at ..
- Mechanisms of action of mifepristone and levonorgestrel when used for emergency contraceptionK Gemzell-Danielsson
Department of Woman and Child Health, Division of Obstetrics and Gynecology, Karolinska Hospital Institute, S 171 76 Stockholm, Sweden
Hum Reprod Update 10:341-8. 2004..Recently, treatment with either 10 mg mifepristone or 1.5 mg of levonorgestrel has emerged as the most effective hormonal method for emergency contraception with very low side-effects...
- Levonorgestrel administration in emergency contraception: bleeding pattern and pituitary-ovarian functionAlessandra Tirelli
Department of Obstetrics, Gynecology and Pediatrics Sciences, Obstetrics and Gynecology Unit, Policlinico of Modena, Via del Pozzo 71, Modena, Italy
Contraception 77:328-32. 2008This study was conducted to evaluate the effects of levonorgestrel administration for emergency contraception (EC) on bleeding pattern and pituitary-ovarian function.
- Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/zidovudine, and ethinyloestradiol/levonorgestrel in healthy volunteersSamantha Abel
Pfizer Global R and D, Sandwich, UK
Br J Clin Pharmacol 65:19-26. 2008..on the pharmacokinetics of midazolam, a sensitive probe CYP3A4 substrate; lamivudine/zidovudine, a combination of nucleoside reverse transcriptase inhibitors (NRTIs); and ethinyloestradiol/levonorgestrel, a combination oral contraceptive.
- Levonorgestrel-only dosing strategies for emergency contraceptionLaura B Hansen
Department of Clinical Pharmacy, University of Colorado at Denver and Health Sciences Center, Denver, Colorado 80262 0238, USA
Pharmacotherapy 27:278-84. 2007..States Food and Drug Administration-approved progestin-only dosing strategy for emergency contraception is levonorgestrel 0.75 mg taken as soon as possible within 72 hours of unprotected intercourse, with a second 0...
- Bleeding patterns after use of levonorgestrel emergency contraceptive pillsElizabeth G Raymond
Family Health International, PO Box 13950, Research Triangle Park, NC 27709, USA
Contraception 73:376-81. 2006The objective of this study was to describe bleeding after use of an emergency contraceptive pill (ECP) regimen consisting of 1.5 mg of levonorgestrel in a single dose.
- Effect of a single vaginal administration of levonorgestrel in Carraguard gel on the ovulatory process: a potential candidate for "dual protection" emergency contraceptionVivian Brache
PROFAMILIA, Biomedical Research Department, P O Box 1053, Santo Domingo 10401, Dominican Republic
Contraception 76:111-6. 2007The study was conducted to evaluate the effect of Carraguard vaginal gel containing 0.75 mg of levonorgestrel (CARRA/LNG gel) administered in a single dose at different stages of follicle development over subsequent follicle rupture and ..
- Pharmacokinetic study to compare the absorption and tolerability of two doses of levonorgestrel following single vaginal administration of levonorgestrel in Carraguard gel: a new formulation for "dual protection" contraceptionRegine Sitruk-Ware
Population Council, Center for Biomedical Research, New York, NY 10021, USA
Contraception 75:454-60. 2007The study was conducted to assess levonorgestrel (LNG) serum levels achieved after a single administration of two different doses of Carraguard vaginal gel containing LNG (CARRA/LNG), designed for use as microbicide and contraceptive for ..
- Pharmacokinetics and endometrial tissue levels of levonorgestrel after administration of a single 1.5-mg dose by the oral and vaginal routeLuigi Devoto
Instituto de Investigaciones Materno Infantil, Departamento de Obstetricia y Ginecologia, Medical Faculty, Hospital San Borja Arriaran, University of Chile, Santiago, Chile
Fertil Steril 84:46-51. 2005To determine the pharmacokinetics and endometrial tissue levels of levonorgestrel when taken as a single dose of 1.5 mg either orally or vaginally by healthy women in the periovulatory phase of their menstrual cycle.
- Short term suppression of follicular recruitment and spontaneous ovulation in the cat using levonorgestrel versus a GnRH antagonistK M Pelican
Department of Reproductive Sciences, Conservation and Research Center, Smithsonian s National Zoological Park, Front Royal, VA 22630, USA
Gen Comp Endocrinol 144:110-21. 2005Suppression and subsequent rebound of ovarian activity using a progestin (levonorgestrel; Norplant) versus a GnRH antagonist (antide) was assessed in the domestic cat via fecal estradiol and progesterone metabolite analyses...
- Benefit-risk assessment of the levonorgestrel intrauterine system in contraceptionTiina Backman
Department of Obstetrics and Gynecology, Turku University Hospital, Turku, Finland
Drug Saf 27:1185-204. 2004The levonorgestrel-releasing intrauterine system (IUS) is a long-acting, fully reversible method of contraception...
- Determination of levonorgestrel in human plasma by liquid chromatography-tandem mass spectrometry method: application to a bioequivalence study of two formulations in healthy volunteersLi zi Zhao
School of Pharmaceutical Sciences, Sun Yat Sen University, 74 Zhongshan Road II, and Department of Pharmacy the First Affiliated Hospital, Guangzhou 510080, People s Republic of China
Biomed Chromatogr 22:519-26. 2008A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC/MS/MS) method to determine levonorgestrel in human plasma was developed and fully validated...
- A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 microg ethinyl estradiol combined with 100 microg levonorgestrelSven O Skouby
Department of Obstetrics and Gynecology, Frederiksberg Hospital, University of Copenhagen, DK 2000 Copenhagen F, Denmark
Contraception 71:111-7. 2005To evaluate the impact on lipid and carbohydrate variables of a combined one-third ethinyl estradiol (EE)/levonorgestrel (LNG) dose reduction in oral contraceptives.
- Comparative evaluation of the effectiveness and safety of two regimens of levonorgestrel for emergency contraception in NigeriansA O Arowojolu
Fertility Research Unit, Obstetrics and Gynaecology Department, University College Hospital, Ibadan, Nigeria
Contraception 66:269-73. 2002..To find an acceptable levonorgestrel regimen for emergency contraception in our community, the two-dose regimen 0...
- Postmarketing study of ORTHO EVRA and levonorgestrel oral contraceptives containing hormonal contraceptives with 30 mcg of ethinyl estradiol in relation to nonfatal venous thromboembolismSusan S Jick
Boston Collaborative Drug Surveillance Program, Department of Epidemiology, Boston University School of Medicine, 11 Muzzey Street, Lexington, MA 02421, USA
Contraception 81:16-21. 2010..Concern has been raised that the risk of venous thromboembolism (VTE) in users of the ORTHO EVRA patch is higher compared to users of oral contraceptives (OCs)...
- Intrauterine contraceptives: a review of uses, side effects, and candidatesNoa a Shimoni
Department of Obstetrics and Gynecology, Columbia University Medical Center, New York, New York 10032, USA
Semin Reprod Med 28:118-25. 2010..Pomona, NY), and the levonorgestrel-releasing intrauterine system (LNG-IUS), marketed as Mirena (Bayer HealthCare Pharmaceuticals, Inc...
- Effects of oral and vaginal administration of levonorgestrel emergency contraception on markers of endometrial receptivityC X Meng
Division of Obstetrics and Gynaecology, Department of Women s and Children s Health, Karolinska University Hospital Karolinska Institutet, SE 17176 Stockholm, Sweden
Hum Reprod 25:874-83. 2010The standard regimen of the levonorgestrel-only pill (1.5 mg either in a single dose or in a dose of 0...
- A randomized prospective trial comparing the levonorgestrel-releasing intrauterine system with thermal balloon ablation for the treatment of heavy menstrual bleedingSérgio S de Souza
Professor Aroldo Fernando Camargos Laboratory of Human Reproduction, Teaching Hospital of the Federal University of Minas Gerais, Minas Gerais, Brazil
Contraception 81:226-31. 2010Use of the levonorgestrel-releasing intrauterine system (LNG-IUS) was compared with thermal balloon ablation (TBA) for the treatment of heavy menstrual bleeding (HMB).
- Protease activated receptor-1 is down regulated by levonorgestrel in endometrial stromal cellsS Hague
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Oxford, UK
Angiogenesis 5:93-8. 2002..The use of intrauterine levonorgestrel (LNG) is however, associated with endometrial atrophy and decidualisation of the stroma...
- An open label, comparative study of the effects of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol and 100 microg levonorgestrel on hemostatic, lipids, and carbohydrate metabolism variablesJan Endrikat
Schering AG, Mullerstrasse 178, D 13342 Berlin, Germany
Contraception 65:215-21. 2002..the influence of a dose-reduced oral contraceptive containing 20 microg ethinyl estradiol (EE) and 100 microg levonorgestrel (20 EE) with a reference preparation containing 30 microg EE and 150 microg levonorgestrel (30 EE) on ..
- A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagiaGamal H Sayed
Department of Obstetrics and Gynecology, Faculty of Medicine, Assiut University, Assiut, Egypt
Int J Gynaecol Obstet 112:126-30. 2011To compare the efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) with that of a low-dose combined oral contraceptive (COC) in reducing fibroid-related menorrhagia.
- Contraceptive efficacy of emergency contraception with levonorgestrel given before or after ovulationGabriela Noe
Instituto Chileno de Medicina Reproductiva ICMER, Santiago, Chile
Contraception 81:414-20. 2010We aimed to evaluate whether emergency contraception with levonorgestrel (LNG-EC) administered after ovulation is equally effective to LNG-EC administered before ovulation.
- Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trialMamdouh M Shaaban
Faculty of Medicine, Department of Obstetrics and Gynecology, Assiut University, Assiut 71526, Egypt
Contraception 83:48-54. 2011This study compared the efficacy of the levonorgestrel-releasing intrauterine system (LNG-IUS) to low dose combined oral contraceptive pills (COC) in the management of idiopathic menorrhagia.
- Treatment of menorrhagia with the levonorgestrel intrauterine system versus endometrial resectionO Istre
Department of Obstetrics and Gynecology, Central Hospital of Hedmark County, Hamar, Norway
Fertil Steril 76:304-9. 2001Treatment of menorrhagia with levonorgestrel intrauterine system (LNG IUS) and transcervical resection.
- Double-blind, randomized, placebo-controlled study on the effect of misoprostol on ease of consecutive insertion of the levonorgestrel-releasing intrauterine systemOskari Heikinheimo
Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland
Contraception 81:481-6. 2010..Misoprostol has been studied intensively to produce cervical dilatation. To date, no studies have evaluated the effectiveness, safety or acceptability of this treatment for repeat intrauterine device insertions...
- Risk of venous thromboembolism and the use of dienogest- and drospirenone-containing oral contraceptives: results from a German case-control studyJürgen Dinger
Director, ZEG Berlin Center for Epidemiology and Health Research, Invalidenstrasse 115, 10115 Berlin, Germany
J Fam Plann Reprod Health Care 36:123-9. 2010..e. containing < or =30 microg EE), particularly oral contraceptives containing levonorgestrel (LNG)...
- A single midcycle dose of levonorgestrel similar to emergency contraceptive does not alter the expression of the L-selectin ligand or molecular markers of endometrial receptivityWilder Alberto Palomino
Instituto de Investigaciones Materno Infantil, Universidad de Chile, Santiago de Chile, Chile
Fertil Steril 94:1589-94. 2010To examine the effects of a single-dose of 1.5 mg of levonorgestrel (commonly used as emergency contraceptive) on endometrial receptivity biomarkers through the oral or vaginal route.
- Levonorgestrel-releasing intrauterine device insertion ameliorates leiomyoma-dependent menorrhagia among women of reproductive age without a significant regression in the uterine and leiomyoma volumesMehmet Murat Naki
Obstetrics and Gynecology Department, Dr Lutfi Kirdar Kartal Research and Training Hospital, Kartal, Istanbul, Turkey
Fertil Steril 94:371-4. 2010b>Levonorgestrel- (LNG) releasing intrauterine device (IUD) insertion revealed significant reduction in visual bleeding scores and spotting with an increase in amenorrhea and uterine pulsatility index scores...
- A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagiaJan Endrikat
Bayer Inc, Toronto, Ontario, Canada
J Obstet Gynaecol Can 31:340-7. 2009To evaluate the efficacy of a levonorgestrel-releasing intrauterine system (LNG-IUS) compared with a combined oral contraceptive containing 1 mg norethindrone acetate and 20 mg ethinyl estradiol (OC1/20) in reducing menstrual blood loss (..
- Development of an animal experimental model to study the effects of levonorgestrel on the human endometriumM L Alvarez Gonzalez
Laboratory of Tumor and Development Biology, GIGA Research, B23, University de Liège, Sart Tilman, B 4000 Liege, Belgium
Hum Reprod 24:697-704. 2009..This study was designed to develop an animal model to test the response of endometrium to local progestin delivery...
- Nasal delivery of levonorgestrel for contraception: an experimental study in ratsAliasgar Shahiwala
Pharmacy Department, Faculty of Technology and Engineering, M S University of Baroda, Kalabhavan, Vadodara 390 001, Gujarat, India
Fertil Steril 81:893-8. 2004To ascertain the nasal bioavailability of Levonorgestrel and change formulation components to provide long-term effective concentrations of the drug in blood...
- Effects of doxycycline on serum and endometrial levels of MMP-2, MMP-9 and TIMP-1 in women using a levonorgestrel-releasing subcutaneous implantShumei Zhao
Department of Obstetrics and Gynecology, CONRAD Clinical Research Center, Jones Institute for Reproductive Medicine, Eastern Virginia Medical School, Norfolk, VA 23507, USA
Contraception 79:469-78. 2009Endometrial spotting and/or bleeding (ESB) occurs in levonorgestrel subcutaneous implant (LNG SI) users. Matrix metalloproteinases (MMPs) may play a role in ESB.
- The Femilis LNG-IUS: contraceptive performance-an interim analysisDirk Wildemeersch
Outpatient Gynaecological Clinic and Training Centre, Ghent, Belgium
Eur J Contracept Reprod Health Care 14:103-10. 2009To provide an update on the experience with the Femilis levonorgestrel-releasing intrauterine system (LNG-IUS) used for up to five years by parous and nulliparous women, particularly with regard to its contraceptive performance.
- A RCT of LNG-IUD vs. DMPA for young postpartum womenNancy Stanwood; Fiscal Year: 2005..The levonorgestrel intrauterine device (LNG-IUD) is a very effective, well-tolerated contraceptive...
- Family Planning Promotion in HIV Infected ZambiansSusan Allen; Fiscal Year: 2005..Cost- effectiveness will be determined with methods developed jointly by experts in the fields of HIV therapy in Africa and contraception. ..
- UNDERSTANDING OVARIAN CONTROL IN RARE BIOMEDICAL MODELSKATHARINE PELICAN; Fiscal Year: 2006..leuprolide acetate (Lupron), a gonadotropin releasing hormone (GnRH) agonist; 2) Antide, a GnRH antagonist; 3) levonorgestrel (Norplant), a progestogen implant; and 4) altrenogest (Regumate), an oral progestogen...
- Obesity Prevention Tailored for Health IIKIM DANIEL REYNOLDS; Fiscal Year: 2010..Two 24-hour recalls will be completed at each assessment period. BMI and physical activity will be objectively measured through height and weight assessments, and through the use of accelerometry to assess physical activity. ..
- Suppression of Breakthrough Bleeding in LNG-IUS UsersRobert Brenner; Fiscal Year: 2004The Mirena(c) (Leiras, OY, Finland) is an intrauterine system (IUS) that releases levonorgestrel (LNG) and provides women with highly effective contraception for 5 years...
- Suppression of Breakthrough Bleeding in LNG-IUS UsersOv Slayden; Fiscal Year: 2006The Mirena(c) (Leiras, OY, Finland) is an intrauterine system (IUS) that releases levonorgestrel (LNG) and provides women with highly effective contraception for 5 years...
- Mifepristone for Prevention of Breakthrough BleedingJohn Jain; Fiscal Year: 2004..Mifepristone has been shown to decrease breakthrough bleeding in women using levonorgestrel implants...
- Progestin Effects on Uterine Hemostasis & AngiogenesisCharles Lockwood; Fiscal Year: 2006..abstract_text> ..
- Enhancing Childrens' and Parents' Asthma ManagementSharon Horner; Fiscal Year: 2006..Follow-up data will be collected 4 months (Time 3) and 8 months (Time 4) later and analyzed. ..
- St. John's Wort Effects on LevonorgestrelPatricia Murphy; Fiscal Year: 2006..John's Wort (Hypericum perforatum), on metabolism of levonorgestrel in a dosing regimen for emergency contraception...
- Conspiracies, Perceived Discrimination & Sexual BehaviorSheryl Thorburn; Fiscal Year: 2003..Findings from this study will inform efforts to prevent HIV and other STDs, as well as unintended pregnancy, among African Americans nationally. ..
- Clinical Translational Research in Transplant NephrologyBryan Becker; Fiscal Year: 2006..It will also work to meet the NIH's goal of increasing the number of physician-scientists conducting high-quality patient-oriented research. ..